Lawsuit over migraine deal could be good for Amgen, analysts say

The Novartis lawsuit only adds potential upside to Amgen, RBC Capital Markets analyst Kennen MacKay wrote in a note to clients on Friday. Aimovig is “on track to achieve blockbuster status,” he said, adding that he predicts up to $3.5 billion in annual global sales and sees significant gains for Amgen if the company can regain full rights to the migraine drug.